Belkin Laser, Israel-based glaucoma laser treatment developer linked to Tel Aviv University faculty, has closed a $12.3m series B round co-led by Santen Ventures, the corporate venturing fund for pharmaceuticals firm Santen.
The round was co-led by Rimonci Capital and also included eye care product developer BioLight Life Science, ophthalmological holding company C-Mer Eye Care and CR-CP Life Science Fund, a joint venture of conglomerates China Resources and Charoen Pokphand.
Founded in 2013, Belkin Laser is working on a non-invasive laser treatment for glaucoma to supplant topical medications. Surgeons using the laser are guided with high-resolution images captured with Belkin’ computer vision-driven eye tracker.
The technology is the brainchild of Michael Belkin, a professor emeritus of Tel Aviv University’s Eye Institute.
Belkin Laser previously collected $2.5m of equity funding in a 2017 round backed by offshore and marine deck machinery firm Zicom Holdings and Rimonci, according to Globes.
The money followed $1.5m already raised from Israel’s Chief Scientist’s Office, accelerator RAD Biomed and private investors including Gur Muntzer.
– A version of this article first appeared on our sister site, Global Corporate Venturing.

Israel-based glaucoma laser treatment developer Belkin Laser has closed a $12.3m series B round co-led by Santen Ventures, the corporate venturing fund for pharmaceuticals firm Santen.

The round was co-led by Rimonci Capital and also included eye care product developer BioLight Life Science, ophthalmological holding company C-Mer Eye Care and CR-CP Life Science Fund, a joint venture of conglomerates China Resources and Charoen Pokphand.

Founded in 2013, Belkin Laser is working on a non-invasive laser treatment for glaucoma to supplant topical medications. Surgeons using the laser are guided with high-resolution images captured with Belkin’ computer vision-driven eye tracker.

The technology is the brainchild of Michael Belkin, a professor emeritus of Tel Aviv University’s Eye Institute.

Belkin Laser previously collected $2.5m of equity funding in a 2017 round backed by offshore and marine deck machinery firm Zicom Holdings and Rimonci, according to Globes.

The money followed $1.5m already raised from Israel’s Chief Scientist’s Office, accelerator RAD Biomed and private investors including Gur Muntzer.